Table 4 Selected phase II trials investigating targeted therapies in preoperative setting
Auto (year) | Type of metastases | No | Treatments | Resectability rate | ORR | Perioperative complications |
|---|---|---|---|---|---|---|
Gruenberger (2008) [49] | Potentially resectable | 56 | Bevacizumab + XELOX | 93% | 73% (CR = 8.9%; PR = 64.3%) | Acceptable |
Wong (2011) [50] | Not suitable for upfront resection | 46 | Bevacizumab + XELOX | 40% | 78% | No grade 3-4 complications |
Shimada (2011) [51] | Unresectable | 7 | Bevacizumab + FOLFIRINOX | 71% | 100% | No grade 3-4 complications |
Folprecht (2010) [52] | Unresectable | 114 | Cetuximab + FOLFOX or FOLFIRI | 60% | 70% in K-RAS wild type tumors (R0 = 34%: 38% with FOLFOX vs 30% with FOLFIRI) | Acceptable |